Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. Summary
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
3.76(c) 3.75(c) 3.715(c) 3.655(c) 3.645(c) Last
20 408 24 209 20 484 17 770 13 860 Volume
-3.09% -0.27% -0.93% -1.62% -0.27% Change
More quotes
Estimated financial data (e)
Sales 2021 4,32 M 5,06 M 5,06 M
Net income 2021 -29,8 M -34,9 M -34,9 M
Net Debt 2021 5,59 M 6,55 M 6,55 M
P/E ratio 2021 -1,86x
Yield 2021 -
Sales 2022 12,3 M 14,4 M 14,4 M
Net income 2022 -28,5 M -33,4 M -33,4 M
Net Debt 2022 21,7 M 25,5 M 25,5 M
P/E ratio 2022 -15,2x
Yield 2022 -
Capitalization 57,6 M 67,5 M 67,5 M
EV / Sales 2021 14,6x
EV / Sales 2022 6,44x
Nbr of Employees 89
Free-Float 79,3%
More Financials
Company
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D... 
More about the company
Ratings of Celyad Oncology SA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CELYAD ONCOLOGY SA
09/20CELYAD ONCOLOGY SA(ENXTBR : CYAD) dropped from S&P Global BMI Index
CI
09/08CELYAD ONCOLOGY : Supplement n░1 to the Registration Document
PU
09/01CELYAD ONCOLOGY : announces September 2021 Conference Schedule
PU
09/01CELYAD : Oncology Announces September 2021 Conferences Schedule
AQ
08/06CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Ma..
MT
08/04CELYAD ONCOLOGY : Reports First Half 2021 Financial Results and Recent Business Highlights..
PU
08/04CELYAD : Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
AQ
08/04Celyad Oncology Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
07/29CELYAD : Oncology to Announce First Half 2021 Financial Results and Host Conference Call
AQ
07/20CELYAD ONCOLOGY : Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based..
BU
07/20Celyad Oncology SA Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-b..
CI
07/13CELYAD : Oncology to Host Virtual Research & Development Webinar on July 20th
AQ
07/07CELYAD : Oncology to Participate at the William Blair Biotech Focus Conference 2021
AQ
06/30CELYAD ONCOLOGY SA : Crossing thresholds
CO
06/11CELYAD ONCOLOGY : Press release issued by the Company on June 11, 2021 (Form 6-K)
PU
More news
News in other languages on CELYAD ONCOLOGY SA
09/01CORRIGE ET REMPLACE : Celyad Oncology annonce sa participation à plusieurs Conférences en ..
09/01CELYAD ONCOLOGY : annonce sa participation à plusieurs Conférences en juin 2021
08/30Brussel opent stabiel
08/26BRUSSELS STOCK EXCHANGE : Brussel sluit lager
08/20Brussel weer in het rood
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Chart CELYAD ONCOLOGY SA
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | CYAD | BE0974260896 | MarketScreener
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,65 €
Average target price 14,75 €
Spread / Average Target 305%
EPS Revisions
Managers and Directors
Filippo Joseph Petti Director, Chief Executive & Financial Officer
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Peggy Sotiropoulou Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CELYAD ONCOLOGY SA-44.94%67
MODERNA, INC.315.47%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.43.03%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939